dr m laban
Tanta fever hospital scientific activity
sunday
12-8-2018
Blood transfusion
Aims of Transfusion Center
To care for the donor - ensure act of donation does not harm donor.
Provision of Blood of the best possible quality and safety for the patient receiving it.
Safe blood transfusion means:
Compatible and without transmission of infection
The Safest blood transfusion is No
transfusion
Blood donation
Careful donor selection with donor interview.
Age: not less than 17 years.
Pulse: between 50-100 beat / minute without irregularities.
Blood pressure: systole<180mmHg, diastolic <100mmHg.
Temperature: <37.5C
Hemoglobin:>12g/dl, Hct>38%
Site of vein puncture must be free of lesions and infections.
ABO grouping.
Rh typing.
Cross matching
Laboratory screening test for:-
HBsAg.
HCV Ab.
HIV.
HTLV1.
HTLV2.
Blood grouping means:-
the determination of the antigens of a specific group on the red cells
and the antibodies relevant to this group in the normal serum.
how to select a healthy donor & care of donor .A healthy donor is one of the most vital part of transfusion medicine for safe transfusion of blood & blood product
how to select a healthy donor & care of donor .A healthy donor is one of the most vital part of transfusion medicine for safe transfusion of blood & blood product
Notes about blood hemoglobin estimation, lecture notes to Medical Laboratory Students at Medical Laboratory Technology, Middle Technical University, Baqubah, Iraq
All about blood collection and handling, lecture notes to Medical Laboratory Students at Medical Laboratory Technology, Middle Technical University, Baqubah, Iraq
blood and blood component have an important role in transfusion medicine. when blood contain all its part and no separation is done thats known as whole blood but when you centrifuge and separate it that is know as component. transfusion of whole blood is now adays absolute from transfusion service and blood components are transfuses now a days which is a good practice and beneficial for the patient
Blood transfusion is the process through which blood and blood products are transferred to circulation intravenously. Early transfusions used whole blood but modern medical practice commonly used components of blood.It helps to replace blood lost during injury or surgery. It is a life saving procedure. before transfusion of blood it is necessary to know your blood group type. As blood group o is considered as universal donor and blood group AB considered as universal accepter.
Blood transfusion are relatively safe but can be fatal if incorrectly administered. Donated blood can be processed into components such as PCV, FFP, Platelets, Cryoprecipitate. Doctors and nurses plays a major role in blood transfusion. They should follows all safety precautions throughout all steps of administrating procedure.
Notes about blood hemoglobin estimation, lecture notes to Medical Laboratory Students at Medical Laboratory Technology, Middle Technical University, Baqubah, Iraq
All about blood collection and handling, lecture notes to Medical Laboratory Students at Medical Laboratory Technology, Middle Technical University, Baqubah, Iraq
blood and blood component have an important role in transfusion medicine. when blood contain all its part and no separation is done thats known as whole blood but when you centrifuge and separate it that is know as component. transfusion of whole blood is now adays absolute from transfusion service and blood components are transfuses now a days which is a good practice and beneficial for the patient
Blood transfusion is the process through which blood and blood products are transferred to circulation intravenously. Early transfusions used whole blood but modern medical practice commonly used components of blood.It helps to replace blood lost during injury or surgery. It is a life saving procedure. before transfusion of blood it is necessary to know your blood group type. As blood group o is considered as universal donor and blood group AB considered as universal accepter.
Blood transfusion are relatively safe but can be fatal if incorrectly administered. Donated blood can be processed into components such as PCV, FFP, Platelets, Cryoprecipitate. Doctors and nurses plays a major role in blood transfusion. They should follows all safety precautions throughout all steps of administrating procedure.
A PowerPoint presentation outlining the physiology of blood transfusion, and clinical precautions to take in preventing and managing blood transfusion reactions.
NURSES PLAY AN IMPORTANT ROLE IN THE TRANSFUSION OF BLOOD PRODUCTS. THEREFORE, IT IS NECESSARY TO UNDERSTAND ABOUT BLOOD, IT'S COMPONENTS, AND PRE-INTRA-POST TRANSFUSION RESPONSIBILITY.
Blood Transfusion
Blood transfusion is the process of transferring blood or blood based products from one person into the circulatory system of another. Safe blood transfusion should be safe to both the donor and the recipient. Blood transfusions can be life saving in some situations such as -Massive blood loss due to trauma or can be used to replace blood lost during surgery.BT may also be used to treat a severe anemia orThrombocytopenia caused by a blood disease.People suffering from hemophilia or sickle disease may require frequent transfusion.
Define blood transfusion
Enlist the purpose of blood transfusion
Brief the history of blood transfusion
Describe various component of blood
Understand types of blood transfusion
Perform the steps of the procedure
Recognize the adverse reaction of blood transfusion
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
5. 1628
1665-’66
1667
Harvey
Discovered Circulation of Blood
Wilkins & Lower
Transfusions from dog to dog
Jean-Baptiste Denis
Performed first recorded blood
transfusions from animals to humans
4
HISTORY OF BLOOD
TRANSFUSIONS
7. AIMS OF TRANSFUSION
CENTER
6
1. To care forthe donor- ensure
act of donation does not harm
donor.
2. Provision of Blood of the best
possible quality and safety for
the patient receiving it.
11. BLOOD DONATION
10
Careful donorselection with donor
interview.
Age: not less than 17 years.
Pulse: between 50-100 beat /minute without
irregularities.
Blood pressure: systole<180mmHg, diastolic
<100mmHg.
Temperature: <37.5C
Hemoglobin:>12g/dl, Hct>38%
Site of vein puncture must be free of lesions
and infections.
13. BLOODGROUPING
12
Blood grouping means:-
• the determination of the antigens of a
specific group on the red cells
•and the antibodies relevant to this
group in the normal serum.
16. 16
Anindividual's redcellgroupis determinedby
Suspending washed red cells withSuspending washed red cells with
diluted anti-A, anti-B and anti Rh (D).diluted anti-A, anti-B and anti Rh (D).
Serum is simultaneously incubatedSerum is simultaneously incubated
with group A, B and 0 cells to confirm thewith group A, B and 0 cells to confirm the
presence of the expected naturallypresence of the expected naturally
occurring ABO antibodies.occurring ABO antibodies.
Agglutination indicates a positive testAgglutination indicates a positive test.
18. 19
The blood must be
•kept in the fluid state.
•living tissue.
•Metabolically viable.
•Free frombacterial infection.
The blood kept in the fluid stat by the
addition of acid citrate dextrose (ACD).
19. RBC COMPATIBILITY CHART
20
In addition to donating to the same blood group;
type O blood donors can give to A, B and AB;
blood donors of types A and B can give to AB.
20. PLASMA COMPATIBILITY CHART
22
In addition to donating to the same blood group;
plasma from type AB can be given to A, B and O;
plasma from types A and B can be given to O.
22. 24
Compatibility testing
• Cross-matching entails
suspension of red cells from a donor
pack with recipient serum,
incubation to allow reactions to
occur, and examination for
agglutination.
24. 27
• Whole blood:- in major blood loss.
• Component therapy : to face an
individual Case needs.
25. • Whole Blood is rarely given because it is
wasteful and sometimes harmful to give
blood components that are not needed.
• It is only necessary when very large
amounts of blood have been lost,
otherwise blood components are given
31. BLOOD COMPONENT PREPARATION
+
30M, 4H
1G/DL
PACKED
RED CELLS
Shelf life 45
days at 40
C
Rare group blood
can be frozen in
glycerol.
Shelf Life: 10 years
PLATELET
CONCENTRATE
Shelf life: 3-5 days at
20-240
C on shaker
1 PACK=150250ml
Hct:60-75%
RBC,W,P- warmed
RDP=50-60ML
=35,000,REC,W
SDP=150-300ML=
150,5000,000=
RBC,W
4H, 30-60M
1RDP/10GK=
- ,5 10 000
SDP=30-60,000
1 PACK=450ml
Hct:37-39%
RBC,W,P,F
-Warmed
20 ML/KG
+
30M, 4H
1G/DL
WB
Shelf life 35
days at 4 C
34
32. CRYOPRECIPITATE
1. Fibrinogen
2. Factor VIII (80
U/bag)
3. von Willebrand’s
Factor
4. Factor XIII
FRESH FROZEN
PLASMA
Stored at minus 300
C
1. All coag factors
2. Fibrinogen
3. Antithrombin
4. Albumin
5. Protein C and S
CRYOSUPERNATE
Factor IX
1 PACK=200=250ML
10-15ml/kg
Water bath 30-37c
6H OF thawing,
2H
-20 30%
1 PACK=20=30ML
1 pack/10kg
Water bath 30-37c
Immediately,
Over 10-15 min
1
PACK=150
-250ml
10-15ml/kg
Water bath
30-37c
6H OF thawing, 2H
33. Plasma drivativesPlasma drivatives
10ml/min
Human albmin
5%
Human albmin
20%
Factor VIII
CONCENTRATE
Bottle=400 ml
50mg/ml
1g/kg
Bottle=100 ml
200-250mg/ml
1g/kg
0.2-0.4ml/min
1 VIALS=250=500 iu
1UNIT= 2%
ACTIVITY
HL:12H
35
34. Anti-RhD Ig
Large
amount FXI
FII, FVII, X
HL: 24H
1 VIALA=150-300 ug
50-75 uglkg
Slowly (5 min)
Once 2 weeks
1vials=0.5,1,
2.5, 5 gm
400 mg/kg/day
5 days IVIg
HBIg,rabis,
Tetanus
Varicella
zoster
Once or repeated IMIg
MULTIFACTO
CONCENTRATE
35. Frozen Red Blood Cells have been frozen to
extend theirstorage period.
Very rare blood types are frozen to insure
they are always on hand.
36. • Platelet Rich Plasma is an intermediate
stage in the production of platelet
concentrate and plasma components.
• Plasma is the yellow liquid portion of
blood. It is also a source of proteins that
stop bleeding by forming blood clots.
• Frozen Plasma to be manufactured into
derivatives is stored and shipped in the
frozen state.
37. • Fresh Frozen Plasma must be processed
and frozen within eight hours of the
whole blood donation to preserve the
less stable clotting proteins. It is used
mainly for people with bleeding
complications.
• Cryoprecipitate, a part of the plasma,
contains two important clotting factors
found in whole blood. It is used to treat
two common clotting disorders.
38. Fractionation
is the process of breaking plasma down into
"fractions."When plasma gets mixed with certain
chemicals, proteins can be separated and
processed into products which are stable and
easily stored. Some of the common fractions are
• Albumin
used in the treatment of certain kidney and liver diseases. Because of
the relative simplicity of storage and administration, it is also used
for emergency cases, such as accident or shock victims, particularly
where facilities for administering blood are not available or where
time does not permit its use.
• PlasmaProteinFraction
similarto albumin; the two products are often used interchangeably.
39. GammaGlobulin
contains the antibodies in plasma and is
able to modify or prevent measles and other
infectious diseases, such as some varieties
of hepatitis.
HBIg, VZIg
are gamma globulin products prepared from
the plasma of donors with high levels of
specific desirable antibodies.
40. Lyophilized FactorVIII
- concentrates are used forthe treatment of
Hemophilia A.
OtherClotting FactorDerivatives
-contain concentrated amounts of specific clotting
factors and are used in certain less common
clotting disorders.
- Platelet Concentrates are needed by patients to
control bleeding in thrombocytopenia and platelet
function disorders.
55. MANAGEMENT OF ACUTE TRANSFUSION
REACTION:
• Stop blood infusion and save the accused
blood bag.
• Keep the intravenous line open and give slow
drip of saline.
• Draw a post-reaction blood sample from the
other vein.
• Record patient’s urine output for the next 6-12
hours.
52
56. Send the following items to the transfusionSend the following items to the transfusion
laboratory:laboratory:
• The accused blood bag with the administration setThe accused blood bag with the administration set
• Post-reaction patient’s blood sample for bloodPost-reaction patient’s blood sample for blood
group re-checking and re-cross-matching.group re-checking and re-cross-matching.
• Urine sample voided after the transfusion reaction.Urine sample voided after the transfusion reaction.
53
MANAGEMENT OF ACUTE TRANSFUSION REACTION:
57. LABORATORY PROCEDURES FOR
AHTR
• Check the identifying information on: The blood
bag , pretransfusion blood sample and label on the
post-reaction samples
• Re-check blood grouping of the pre-transfusion,
post-reaction samples , blood bag and re-check
cross-matching.
• Look for hemolysis in the post-reaction blood
sample.
54
58. LABORATORY PROCEDURES FOR
AHTR:• Perform DAT on patient’s RBC in the pretransfusionPerform DAT on patient’s RBC in the pretransfusion
and post-reaction blood samples. Examineand post-reaction blood samples. Examine
microscopically .microscopically .
• Examine urine sample for hemoglobinuria and necroticExamine urine sample for hemoglobinuria and necrotic
tubular cells.tubular cells.
• Estimate serum bilirubin ,LDH, creatinine, electrolytes.Estimate serum bilirubin ,LDH, creatinine, electrolytes.
N.B.Negative results for re-checking, DAT, hemolysis andN.B.Negative results for re-checking, DAT, hemolysis and
hemoglobinuria rule out ABO incompatibilities.hemoglobinuria rule out ABO incompatibilities.
55
59. THERAPYOFAHTR
The main lines of therapy are:The main lines of therapy are:
• Supportive therapy for theSupportive therapy for the
cardiovascular system and renalcardiovascular system and renal
system by IV fluids and diureticsystem by IV fluids and diuretic
such as mannitol.such as mannitol.
• Bronchodilators and low-doseBronchodilators and low-dose
dopamine.dopamine.
• Replacement for coagulation such asReplacement for coagulation such as
FFP, platelets and cryoprecipitate ifFFP, platelets and cryoprecipitate if
there is impending DIC.there is impending DIC.
56
60. THERAPYOFAHTR
Monitoring of therapy for AHTRMonitoring of therapy for AHTR
• Renal status by creatinine and urine output.Renal status by creatinine and urine output.
• DIC by PT, PTT, platelet and fibrinogen.DIC by PT, PTT, platelet and fibrinogen.
• Degree and progress of hemolysis by LDH.Degree and progress of hemolysis by LDH.
57
61. ALLERGIC REACTIONS RELATED
TO BLOOD TRANSFUSION
58El-Shanshory 2011
It is one of the common reactions and
ranges from:
1.Severe fatal reaction (anaphylactic
allergic reaction) .
2.To very mild skin (urticarial) reaction.
62. ALLERGIC URTICARIAL
REACTION• It is a common reaction (1% of transfusion) and is
manifested by a sense of itching, with urticarial rash.
• Pathogenesis: it is an immunological reaction
between soluble antigen in the transfused blood
units and antibodies in the patient.
• Treatment:
– Transient stopping of transfusion, give
antihistamines.
– Restart transfusion with slow rate.
• Prevention: use of washed RBCs and pre-
transfusion of antihistamines.
59
63. ANAPHYLACTIC TRANSFUSION REACTION
60
Definition:
it is acute onset of hypotension, bronchospasm,
chills, fever, and urticarial following transfusion
blood , plasma or products of blood.
Pathophysiology:
it is the result of massive release of vasoactive
and smooth muscle-reactive mediators following
acute antigen-antibody interaction.
Commonly, it occurs in IgA deficient patients who
developed anti-IgA (Ag)
The incidence of anaphylatic reaction:
it is reported to occur in 1 in 20,000 or to 50,000
recipients.
Clinical picture of anaphylactic reaction: Most
patients show sudden :-
* severe hypotension. * Flushing.
* bronchospasm, dyspnea. * Chills.
* vomiting ,diarrhea. * wide-spread oedema,
urticarial rash .
64. LABORATORY DIAGNOSIS OF ANAPHYLACTIC REACTION:
TREATMENT OF ANAPHYLACTIC
REACTION:
PREVENTION OF ANAPHYLACTIC
REACTION:
• Detection of IgA.
• Detection of anti-IgA by passive hemagglutination assay
utilized IgA coated RBCs.
• Stop transfusion immediately.Stop transfusion immediately.
• Antihistamines.Antihistamines.
• Epinephrine.Epinephrine.
• Fluid therapy to maintain the blood pressure.Fluid therapy to maintain the blood pressure.
• Use washed RBCs in suspected patients.Use washed RBCs in suspected patients.
62
65. DELAYEDHEMOLYTIC TRANSFUSION REACTION IN SOME
CLINICAL CONDITIONS
DHTR in solid organ transplantation
In minor incompatibilityIn minor incompatibility :-:-
• the contaminant lymphocytes in the transplanted organ (liver,the contaminant lymphocytes in the transplanted organ (liver,
kidney, heart) may produce antibodies against the recipientkidney, heart) may produce antibodies against the recipient
RBCs (for example O liver donor and A recipient).RBCs (for example O liver donor and A recipient).
• These antibodies may produce DHTR within 7 days afterThese antibodies may produce DHTR within 7 days after
transplantation and may last for 1 month.transplantation and may last for 1 month.
• It may be complicated by renal failure.It may be complicated by renal failure.
• The patient is given O Rh negative RBCs.The patient is given O Rh negative RBCs.
In major incompatibility:In major incompatibility:
• The donor’s organ carrying ABO antigens that can beThe donor’s organ carrying ABO antigens that can be
agglutinated by the recipient antibodies .agglutinated by the recipient antibodies .
• It is recommended to carry pre-transplant plasmapheresis .It is recommended to carry pre-transplant plasmapheresis . 63
66. DHTR following hemopoietic stem cell transplantation(HSDT)
In minor-incompatibilityIn minor-incompatibility::
• The contaminant cells of the donor (lymphocytes) in theThe contaminant cells of the donor (lymphocytes) in the
HSCT may produce antibodies.HSCT may produce antibodies.
• Treatment:Treatment:
Transfusion of O cells to dilute the patients RBCs.Transfusion of O cells to dilute the patients RBCs.
In severe cases, RBCs exchange with blood group OIn severe cases, RBCs exchange with blood group O
RBCs if there is rapid bone marrow engraftment .RBCs if there is rapid bone marrow engraftment .
InIn major incompatibilities:major incompatibilities:
• The donor’s BM RBCs are hemolysed by the patient’sThe donor’s BM RBCs are hemolysed by the patient’s
antibodies.antibodies.
• Treatment:Treatment:
1)Depletion of the donor’s bone marrow from RBCs1)Depletion of the donor’s bone marrow from RBCs
2)Pre-transplantation plasmapheresis.2)Pre-transplantation plasmapheresis.
In minor-incompatibilityIn minor-incompatibility::
• The contaminant cells of the donor (lymphocytes) in theThe contaminant cells of the donor (lymphocytes) in the
HSCT may produce antibodies.HSCT may produce antibodies.
• Treatment:Treatment:
Transfusion of O cells to dilute the patients RBCs.Transfusion of O cells to dilute the patients RBCs.
In severe cases, RBCs exchange with blood group OIn severe cases, RBCs exchange with blood group O
RBCs if there is rapid bone marrow engraftment .RBCs if there is rapid bone marrow engraftment .
InIn major incompatibilities:major incompatibilities:
• The donor’s BM RBCs are hemolysed by the patient’sThe donor’s BM RBCs are hemolysed by the patient’s
antibodies.antibodies.
• Treatment:Treatment:
1)Depletion of the donor’s bone marrow from RBCs1)Depletion of the donor’s bone marrow from RBCs
2)Pre-transplantation plasmapheresis.2)Pre-transplantation plasmapheresis.
64
67. DHTRFOLLOWING BLOODTRANSFUSION IN SICKLE CELL
DISEASE
• The frequency of alloimmunization in sickle cell disease afterThe frequency of alloimmunization in sickle cell disease after
repeated transfusion is about 20-30%.repeated transfusion is about 20-30%.
• Some patients may develop warm-reacting auto-antibodies.Some patients may develop warm-reacting auto-antibodies.
• Clinically, DHTR in sickle cell disease:Clinically, DHTR in sickle cell disease:
• Signs of sickle cell crisis.Signs of sickle cell crisis.
• Development of more anemia.Development of more anemia.
• Reticulocytopenia secondary to suppression ofReticulocytopenia secondary to suppression of
erythropoiesis by blood transfusion and hemolysis oferythropoiesis by blood transfusion and hemolysis of
reticulocytes.reticulocytes.
• Prevention and treatment:Prevention and treatment:
• RBCs phenotyping for Kell, kid ….. and Rh areRBCs phenotyping for Kell, kid ….. and Rh are
recommended before the start of long term bloodrecommended before the start of long term blood
transfusion.transfusion.
• Corticosteroid and immunoglobulin during DHTR.Corticosteroid and immunoglobulin during DHTR.
65El-Shanshory 2011
68. POST-TRANSFUSION PURPURA
(PTP(
• Definition:Definition: It is acute episode of severe thrombocytopeniaIt is acute episode of severe thrombocytopenia
occurring about one week after blood transfusion.occurring about one week after blood transfusion.
• It usually affectsIt usually affects :-:-
HPA-1aHPA-1a (Human Platelet Antigen)(Human Platelet Antigen) negative pregnant womennegative pregnant women
or HPA-1a negative persons who were repeatedly transfused withor HPA-1a negative persons who were repeatedly transfused with
HPA-1a positive blood componentsHPA-1a positive blood components..
• Incidence:Incidence: It is a very rare complication 1:400,000It is a very rare complication 1:400,000
transfusions as the prevalence of HPA-1a negative persons istransfusions as the prevalence of HPA-1a negative persons is
very low.very low.
• Definition:Definition: It is acute episode of severe thrombocytopeniaIt is acute episode of severe thrombocytopenia
occurring about one week after blood transfusion.occurring about one week after blood transfusion.
• It usually affectsIt usually affects :-:-
HPA-1aHPA-1a (Human Platelet Antigen)(Human Platelet Antigen) negative pregnant womennegative pregnant women
or HPA-1a negative persons who were repeatedly transfused withor HPA-1a negative persons who were repeatedly transfused with
HPA-1a positive blood componentsHPA-1a positive blood components..
• Incidence:Incidence: It is a very rare complication 1:400,000It is a very rare complication 1:400,000
transfusions as the prevalence of HPA-1a negative persons istransfusions as the prevalence of HPA-1a negative persons is
very low.very low.
66
69. PATHOPHYSIOLOGY OF PTP
• The pathophysiology is similar to HDN Hemolytic
disease of the newborn.
• Blood transfusion of HPA-1a positive platelets or
blood donor in a previously expose HPA-1a
negative patient (pregnancy ….) will cause
secondary immune response with marked rise in
anti-HPA-1a antibodies which is followed by
destruction of the patient’s HPA-1a negative
platelets by unknown mechanism. 67
70. • Clinical picture of PTP:
• Most patients are persons who have had previous
transfusion.
• The platelet-count usually drop rapidly within 5-10
days after transfusion with severe hemorrhage
(purpura and GIT bleeding).
• Platelet count rises again within 2-4 weeks.
• Prognosis of PTP: mortality is about 5% from
intracranial hemorrhage.
• Differential diagnosis of PTP
• Auto-immune and drug-induced thrombocytopenia.
• DIC and TTP.
68
71. • Laboratory investigation of PTP:
• Performance of platelet-count.
• Detection of HPA-1a antigen.
• Detection of HPA-1a antibodies.
• BM to exclude bone marrow aplasia.
• Treatment:
• High dose IVIgG.
• Corticosteroids.
• Plasmapheresis.
• Platelet concentrates are of little value and indicated in
severe bleeding. It may cause transfusion related acute
lung injury .
• Prevention:
The patient should be transfused from HPA-1a
negative donor. 69
72. IMMUNOMODULATION EFFECTS OF BLOOD
TRANSFUSION
• Blood transfusion leads to both activation of
immune system (production of alloantibodies)
and suppression of immune-mediated
activities .
• The suppressor effects on the immune system
are :
1.Reduction in CD4/CD8 ratio and natural killers.
2.Impaired lymphocyte mitogenic response.
3.Suppression of delayed hypersensitivity reaction.
4.Induction of state of anergy.
5.Inhibition of neutrophil function.
71
73. CLINICAL EFFECTS OF
IMMUNOMODULATION:
• The adverse post-transfusion
immunomodulation is the result of leucocyte
chimerism and cytokine production:
• Increase cancer recurrence.
• Increase post-operative infection.
• Transfusion-associated graft-versus host
disease.
72El-Shanshory 2011
74. Minimizing the blood transfusionMinimizing the blood transfusion
74
Maintenance of cardiac output by:
• Crystalloid solutions.
• Colloid solution :-
Dextran
Delatin
Hydroxylethy Starch)
• Act from 4-24 hours.
75. BLOOD transfusion alternatives
Hydroxy ethystarchHydroxy ethystarch
(metastarch)(metastarch)
Cool placesCool places
-
45 min
Normal salineNormal saline
ringer lactateringer lactate
Cool placesCool places
Gelatin (hemocel)Gelatin (hemocel)
At room temp<25At room temp<25
5 years5 years
Dextran 60, 70Dextran 60, 70
At room temp<25At room temp<25
1 bootle=
500ml
3 times
Blood lost
4% in 0.9
NaCl
4H
3%dextran 60
in NaCl 0.9%
6% dextran 70
In 5% glucose
Not exceed
25-50ml/kg/24h
12h
6%metastarch
in
NaCl 0.9%
Not exceed
20ml/kg/24h
20-24h
75El-Shanshory 2011